Sorafenib as an adjuvant therapy for resectable hepatocellular carcinoma: A single center experience

被引:0
|
作者
Antoniou, Efstathios A. [1 ]
Margonis, Georgios A. [1 ]
Amini, Neda [2 ]
Anastasiou, Maria [1 ]
Angelou, Anastasios [3 ]
Kim, Yuhree [2 ]
Kouraklis, Grigorios [1 ]
机构
[1] Univ Athens, Sch Med, Laiko Gen Hosp, Dept Propaedeut Surg 2, Athens, Greece
[2] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA
[3] Univ Athens, Sch Med, Laiko Gen Hosp, Dept Surg 1, Athens, Greece
来源
JOURNAL OF BUON | 2016年 / 21卷 / 05期
关键词
hepatocellular carcinoma; liver resection; sorafenib; LIVER RESECTION; PHASE-II; RECURRENCE; METASTASIS; ERLOTINIB; TRENDS; TUMORS; TRIAL;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Resectable hepatocellular carcinoma (HCC) is currently treated with surgical resection without any adjuvant therapy. We sought to assess the value of sorafenib as an adjuvant treatment in that clinical setting. Methods: Of a total of 30 patients, 16 underwent curative -intent liver resection for HCC and subsequently received adjuvant sorafenib, while 14 underwent surgery alone. Clinicopathological characteristics were analyzed and the impact of adjuvant sorafenib on overall survival (OS) was assessed. Results: The median follow up time was 38.2 months. The median patient age was 63.5 and 76.7% of them were male. The majority of patients had a solitary tumor (74.1%) with a median size of 7.75 cm. Five-year OS for the whole cohort was 60.2%. OS for patients who underwent only resection was 52.9 vs 68.1% for patients who underwent resection and received adjuvant sorafenib (p=0.19). Conclusion: Sorafenib seems to be associated with an acceptable safety profile but does not confer any substantial clinical benefit in terms of survival in HCC patients who have undergone curative -intent liver resection.
引用
收藏
页码:1189 / 1194
页数:6
相关论文
共 50 条
  • [11] Adjuvant treatments for resectable hepatocellular carcinoma
    Ishii, Hiroshi
    Yamamoto, Junji
    Ikari, Takaaki
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY, 2008, 15 (05): : 459 - 462
  • [12] Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience
    Endo, Masatsugu
    Nishikawa, Hiroki
    Kita, Ryuichi
    Kimura, Toru
    Ohara, Yoshiaki
    Sakamoto, Azusa
    Saito, Sumio
    Nishijima, Norihiro
    Nasu, Akihiro
    Komekado, Hideyuki
    Osaki, Yukio
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 4 (04) : 515 - 522
  • [13] SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: EXPERIENCE IN SINGLE INSTITUTE
    Lee, S. S.
    Chang, H. M.
    Lee, J.
    Kim, T. W.
    Kim, K. M.
    Lee, H. C.
    Lee, Y. S.
    Suh, D. J.
    Lee, S. G.
    Kang, Y.
    ANNALS OF ONCOLOGY, 2008, 19 : 179 - 179
  • [14] Experience with sorafenib treatment of hepatocellular carcinoma (HCC) in patients in a Brazilian center
    Alves, Daniele Evaristo
    Alves, Rogerio
    Poletti, Paula
    Gampel, Otavio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [15] Management of Hepatocellular Carcinoma - Experience of a Single Center
    Iliescu, L.
    Mindrut, E.
    Grasu, M.
    Orban, C.
    Tanase, A.
    Toma, L.
    CHIRURGIA, 2014, 109 (02) : 204 - 207
  • [16] Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
    Crook, Christiana J.
    Li, Daneng
    CURRENT ONCOLOGY REPORTS, 2023, 25 (10) : 1191 - 1201
  • [17] Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
    Christiana J. Crook
    Daneng Li
    Current Oncology Reports, 2023, 25 : 1191 - 1201
  • [18] Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience
    Ueshima, Kazuomi
    Nishida, Naoshi
    Kudo, Masatoshi
    DIGESTIVE DISEASES, 2017, 35 (06) : 611 - 617
  • [19] SAFETY AND TOLERABILITY OF SORAFENIB IN CHILD-PUGH B PATIENTS WITH HEPATOCELLULAR CARCINOMA: A SINGLE CENTER EXPERIENCE
    Gupta, Shweta
    Dhar, Sumedha
    Yim, Barbara
    Rosen, Fred
    ANNALS OF ONCOLOGY, 2012, 23 : 56 - 57
  • [20] Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience
    Kudo, Masatoshi
    Ueshima, Kazuomi
    Arizumi, Tadaaki
    DIGESTIVE DISEASES, 2012, 30 (06) : 609 - 616